Insider Selling: Quantum-Si (NASDAQ:QSI) Insider Sells 21,927 Shares of Stock

Quantum-Si Incorporated (NASDAQ:QSI) insider John Vieceli sold 21,927 shares of the stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $1.28, for a total transaction of $28,066.56. Following the sale, the insider directly owned 800,973 shares in the company, valued at approximately $1,025,245.44. The trade was a 2.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Quantum-Si Stock Performance

Shares of QSI stock remained flat at $1.27 during trading hours on Monday. The stock had a trading volume of 5,071,186 shares, compared to its average volume of 3,958,795. Quantum-Si Incorporated has a twelve month low of $0.95 and a twelve month high of $5.77. The company has a market capitalization of $273.67 million, a price-to-earnings ratio of -1.90 and a beta of 2.97. The business’s fifty day moving average price is $1.66 and its 200 day moving average price is $1.58.

Quantum-Si (NASDAQ:QSI) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.17) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.17). Quantum-Si had a negative net margin of 3,677.97% and a negative return on equity of 47.90%. The firm had revenue of $0.55 million for the quarter, compared to analysts’ expectations of $0.60 million. On average, equities analysts predict that Quantum-Si Incorporated will post -0.65 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on QSI shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Quantum-Si in a research note on Monday, December 8th. Canaccord Genuity Group reduced their price target on Quantum-Si from $2.00 to $1.50 and set a “hold” rating on the stock in a report on Monday. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $3.60.

Hedge Funds Weigh In On Quantum-Si

A number of hedge funds have recently modified their holdings of QSI. Prudential Financial Inc. acquired a new position in Quantum-Si in the second quarter valued at about $25,000. JTC Employer Solutions Trustee Ltd purchased a new stake in shares of Quantum-Si in the 2nd quarter valued at approximately $26,000. Cerity Partners LLC acquired a new position in shares of Quantum-Si in the 2nd quarter worth approximately $29,000. Wolverine Asset Management LLC lifted its holdings in shares of Quantum-Si by 140.0% in the 2nd quarter. Wolverine Asset Management LLC now owns 16,501 shares of the company’s stock worth $32,000 after acquiring an additional 9,626 shares during the last quarter. Finally, Capital Investment Advisory Services LLC boosted its position in shares of Quantum-Si by 100.0% during the 3rd quarter. Capital Investment Advisory Services LLC now owns 20,000 shares of the company’s stock worth $28,000 after purchasing an additional 10,000 shares during the period. 39.90% of the stock is currently owned by hedge funds and other institutional investors.

About Quantum-Si

Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.

Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software.